UJVIRA 100mg Infusion

1. Product Introduction

UJVIRA 100mg Infusion is a prescription-only anticancer medication that contains Trastuzumab (100mg) as its active ingredient. Trastuzumab is a monoclonal antibody used in the treatment of certain types of HER2-positive cancers, especially breast cancer and gastric (stomach) cancer. This advanced biologic therapy is specifically designed to target and bind to the HER2 receptor, a protein found in high amounts on the surface of some cancer cells, thereby stopping or slowing the growth of the cancer.

UJVIRA belongs to a class of targeted therapies known as HER2 inhibitors. Unlike conventional chemotherapy, which affects both healthy and cancerous cells, Trastuzumab selectively attacks cancer cells that overexpress the HER2 protein, leading to improved treatment outcomes with reduced toxicity.

The infusion is administered intravenously (IV) under the supervision of a qualified healthcare professional in a hospital or oncology center. It may be used as a standalone therapy or in combination with chemotherapy, hormone therapy, or other cancer medications, depending on the stage and type of cancer being treated.

2. Uses of This Medicine

UJVIRA 100mg Infusion is primarily used for:

• HER2-positive breast cancer (early-stage or metastatic)

• HER2-positive metastatic gastric or gastroesophageal junction cancer

It is often prescribed:

• As adjuvant therapy (after surgery) to reduce the risk of cancer returning

• As first-line treatment for metastatic disease (cancer that has spread)

• In combination with chemotherapy or hormone therapy to enhance effectiveness

3. Benefits of This Medicine

UJVIRA 100mg Infusion offers a range of significant clinical benefits, especially for patients with HER2-positive cancers:

• Targeted Cancer Therapy: Trastuzumab directly targets HER2 receptors, ensuring a precise action on cancer cells while minimizing damage to healthy tissue.

• Improved Survival Rates: Numerous studies have shown that Trastuzumab improves overall survival and disease-free survival, particularly in patients with HER2-positive breast cancer.

• Reduces Cancer Recurrence: When used in early-stage HER2-positive breast cancer, UJVIRA helps prevent the cancer from coming back after surgery or other treatments.

• Enhanced Efficacy When Combined: The infusion shows increased effectiveness when used alongside other chemotherapy agents such as paclitaxel or docetaxel.

• Well-Studied and Globally Accepted: Trastuzumab is a globally recognized and widely used monoclonal antibody with a strong safety and efficacy profile.

• Quality of Life Improvement: By effectively shrinking tumors and delaying progression, UJVIRA may help improve patients’ quality of life and reduce the need for more aggressive interventions.

4. Side Effects

While UJVIRA 100mg Infusion is generally well-tolerated, it may cause side effects in some patients. These can vary depending on individual response, existing health conditions, and concurrent therapies.

Common Side Effects:

• Fever and chills (especially during first infusion)

• Nausea and vomiting

• Headache

• Fatigue and weakness

• Diarrhea

• Rash or skin reactions

Serious Side Effects (Less Common):

• Cardiac toxicity (such as decreased heart function or heart failure)

• Infusion-related reactions (breathing difficulty, chest pain, hypotension)

• Lung problems (pneumonitis or interstitial lung disease)

• Severe allergic reactions (anaphylaxis)

Important: Trastuzumab can affect the heart, especially in patients who have received prior chemotherapy with anthracyclines or have pre-existing heart disease. Regular cardiac monitoring (e.g., echocardiograms) is essential during and after treatment.

Patients should report any symptoms like shortness of breath, swelling, or chest discomfort to their doctor immediately.

5. Frequently Asked Questions (FAQ)

Q1. What is UJVIRA 100mg Infusion used for?
A: UJVIRA is used to treat HER2-positive breast and gastric cancers, either as a standalone treatment or in combination with other cancer therapies.

Q2. How is UJVIRA administered?
A: It is given as an intravenous infusion (IV) by a trained medical professional in a clinic or hospital. The infusion duration may vary depending on whether it’s a loading or maintenance dose.

Q3. How long will I need to take UJVIRA?
A: The duration of treatment depends on your type of cancer, response to therapy, and other factors. In early breast cancer, it’s typically given for 1 year, while in metastatic cases, it may be continued as long as it remains effective.

Q4. Can UJVIRA be used during pregnancy?
A: No. UJVIRA should not be used during pregnancy as it can harm the developing fetus. Women of childbearing age should use effective contraception during and for at least 7 months after treatment ends.

Q5. What precautions should I take before or during treatment?
A: Inform your doctor about any existing heart problems, ongoing infections, or if you’re pregnant or breastfeeding. Regular heart function tests and blood work may be required.

Q6. Are there any food or drug interactions I should be aware of?
A: There are no major food restrictions, but always inform your doctor about all medications and supplements you’re taking to avoid interactions.

Q7. What should I do if I miss a dose?
A: Since UJVIRA is administered in a healthcare setting, scheduling is usually managed by your medical team. If a dose is missed, it will be rescheduled by your doctor without compromising treatment efficacy.

Q8. Is UJVIRA the same as Herceptin?
A: UJVIRA contains Trastuzumab, the same active ingredient as Herceptin. It may be a biosimilar, which means it offers the same safety and effectiveness but may be more affordable.

References